The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN will be composed of a Scientific and Data Coordination Center (DCC), Clinical Centers (CC) , and the NIDDK/NIH as the sponsor of the Network. ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hepatitis; Cystic Fibrosis Liver Disease; and primary sclerosing cholangitis.
The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN is composed of a Scientific and Data Coordination Center (SDCC) and Clinical Centers (CC). ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hepatitis; Cystic Fibrosis Liver Disease; and primary sclerosing cholangitis.
One aspect of the organization's mission is to promote the quality of liver care, including care of patients with cirrhosis. Systematic efforts to improve the care of patients with advanced chronic liver disease have been minimal, however. In addition, the accumulating data show that care targeted at patients with cirrhosis often falls short of the guidelines and recommended standards, and is associated with increased morbidity and resource utilization.
Given these identified gaps in care, the members of the Cirrhosis Quality Collaborative (CQC) seek to develop a Learning Health Network in which continuous improvement of healthcare, technological innovation, and research are all purposefully integrated. The Learning Health Network will be designed to generate and apply the best evidence for the collaborative choices of each patient and provider; to drive the process of discovery as a natural outgrowth of patient care; and to ensure innovation, quality, safety, and value in health care for patients with Chronic Liver Disease.
To that end, AASLD is soliciting requests for proposals from vendors to build, host, and maintain a disease registry software platform that supports the Learning Health Network. The goal of the system is to enroll patients from multiple sites into a single platform with minimal manual data entry.
This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.
The objective of the Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs) is to bring together, on a cooperative basis, basic and clinical investigators to enhance the effectiveness of their research related to digestive and/or liver diseases and their complications. DDRCCs are meant to improve communication among investigators and to integrate, coordinate, and foster interdisciplinary research involving the etiology, treatment, and prevention of digestive and /or liver diseases. To accomplish this, the DDRCC supports a group of established investigators actively conducting programs of important, high-quality research that relates to a common theme in digestive diseases or liver diseases research. Thus, the purpose of a DDRCC is to provide the capability for accomplishments greater than those that would be possible by individual research project grant support alone. Applicants should consult NIDDK staff concerning plans for the development of the DDRCC and the organization of the application.
PSC Partners Seeking a Cure is a nonprofit foundation whose mission is to provide education and support to patients with primary sclerosing cholangitis, their families, and their caregivers and to raise funds for research on the causes, treatments, and cures for PSC, an autoimmune disease that causes the bile ducts inside and outside the liver to become scarred, narrowed, and eventually blocked.
The foundation offers grants of up to $60,000 over two years in support of projects that address a novel, basic, or clinical research question related to PSC and closely allied diseases (such as inflammatory bowel diseases, ulcerative colitis, or Crohn's disease) as they relate to PSC.
Preference will be given to projects that have the potential to discover a cure for the disease and/or that identify novel therapies which may significantly delay time to liver transplantation, prevent disease recurrence following liver transplantation, and/or improve the quality of life of those with PSC.
This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.
i. Purpose: The purpose of these activities is to support the goals of the HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis, 2014-2016 (available at http://aids.gov/pdf/viral-hepatitis-action-plan.pdf) by ensuring Hepatitis B-infected pregnant women are identified so that their infants can receive timely post-exposure prophylaxis, improvements in post-vaccination serologic testing to improve efficiencies, and data collection to assess infant outcomes ii. Outcomes: Increased identification of Hepatitis B-infected pregnant women; increased rates of post-vaccination serologic testing among infants born to Hepatitis B-infected pregnant women; and assessment of factors associated with infant outcomes iii. Strategies and Activities: Collaborations: To maximize opportunities for Hepatitis B prevention through vaccination, referral for care, and treatment of persons found to have chronic Hepatitis B infection, this FOA encourages Perinatal Hepatitis B Prevention Program collaborations and service integration as a program imperative of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Such collaborations can increase efficiency, reduce redundancy, eliminate missed opportunities, and improve outcomes through the use of shared data and services. a. With CDC-funded programs: Applicants should create and build upon internal health department collaborations to improve identification of Hepatitis B-infected pregnant women; screen their household and sexual contacts for Hepatitis B and complete vaccination of susceptible persons; refer persons with chronic Hepatitis B infection for care and treatment; and report infants, household, and sexual contacts with chronic Hepatitis B infection to the National Notifiable Diseases Surveillance System. b. With organizations external to CDC: Opportunities for collaboration with non-CDC organizations will be encouraged; non-CDC organizations may include commercial laboratories and health system
The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.
The purpose of this concept initiative is to promote etiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.
The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US.
Also listed under R01.
ADPKD affects ~500,000 patients in US and ~10 million world-wide with limited treatment options. ADPKD patients develop progressive cyst growth in kidney over decade, eventually leading to deterioration of kidney function combined with severe pain, hematuria and fibrosis/inflammation. Two mutations (Pkd1/pkd2) account for >95% of ADPKD cases, and the dominant nature and high penetration rate of this disease affects patient families in a profoundly negative way in both health care and social interactions. There is currently no FDA approved medicine for ADPKD in US, although vasopressin antagonist and somatostatin mimetics are in phase 3 studies.
GSK aims to deliver innovative medicine to treat ADPKD based on novel mechanism of action. We are particularly interested in agents or targets that function upstream of final cellular proliferative response and have solid genetic/pharmacological evidence supporting the role of such target/agents in human ADPKD. We are also interested in mechanisms/targets that can treat both liver and kidney cyst progression.
We are open to form a partnership or alliance with perspective investigators/sponsors to pursue such new target/agents upon review and approval.
The purpose of this limited competition funding opportunity announcement (FOA) is to continue the support of the Clinical Sites of the NASH Clinical Research Network (NASH CRN) as they complete active clinical treatment trials and continue to longitudinally gather biospecimens and data of children and adults with nonalcoholic fatty liver disease (NAFLD), including steatosis, steatohepatitis, and cirrhosis (NAFLD database study). The NASH CRN has been sponsored by the NIDDK since 2002, and renewed in 2009 and 2014. Research in the NASH CRN has been focused on the etiology, contributing factors, natural history, complications, and therapy of nonalcoholic steatohepatitis.
The purpose of this limited competition funding opportunity announcement (FOA) is to continue the support of the Data Coordinating Center of the NASH Clinical Research Network (NASH CRN) as they complete active clinical treatment trials and continue to longitudinally gather biospecimens and data of children and adults with nonalcoholic fatty liver disease (NAFLD), including steatosis, steatohepatitis, and cirrhosis (NAFLD database study). The NASH CRN has been sponsored by the NIDDK since 2002, and renewed in 2009 and 2014. Research in the NASH CRN has been focused on the etiology, contributing factors, natural history, complications, and therapy of nonalcoholic steatohepatitis.
The purpose of this Notice of Funding Opportunity (NOFO) is to reduce risky alcohol use among women of childbearing age through system-level implementation of alcohol screening and brief intervention (SBI) in health systems providing women’s health services. Risky alcohol use can result in a variety of negative health and social consequences, such as motor vehicle crashes, intimate partner violence, and fetal alcohol spectrum disorders. It is costly, results in over 88,000 deaths annually, and can affect serious medical conditions, such as hypertension, liver disease and certain types of cancer. Health professionals are uniquely positioned to intervene with patients with acute and chronic health conditions caused or exacerbated by risky alcohol use. Alcohol SBI implementation efforts within health systems will focus on development and implementation of: a training and technical assistance plan; alcohol SBI protocols in primary care clinics; system-level approaches that facilitate uptake (e.g., electronic health record integration and performance metrics); an evaluation plan assessing feasibility and impact of system-level implementation; a dissemination plan on promising models and lessons learned; and a sustainability plan. Expected performance outcomes include documenting provider/clinic readiness to conduct alcohol SBI, documenting implementation barriers and proposed solutions, tracking clinic-level data on alcohol SBI, and assessing the use of system-level strategies.
Cigarette smoking and exposure to secondhand smoke (SHS) is the leading preventable cause of death in the United States, resulting in approximately 480,000 premature deaths and 16 million smoking-related illnesses. Cigarette smoking can lead to increased cardiovascular disease, multiple types of cancer, pulmonary disease, adverse reproductive outcomes, and the exacerbation of chronic health conditions. Annual costs associated with tobacco-related illnesses amount to nearly $280 billion in medical expenses and lost productivity. Electronic cigarette (e-cigarette) use among U.S. youth and young adults has increased considerably, growing 900% among high school students from 2011 to 2015. Cancer is the second leading cause of death in the United States, with approximately 1.5 million new diagnoses and over 550,000 deaths each year. Commercial Tobacco use is the leading preventable cause of cancer and cancer deaths. It can cause not only lung cancer but also cancers of the mouth and throat, voice box, esophagus, stomach, kidney, pancreas, liver, bladder, cervix, colon and rectum, and a type of leukemia.
This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data.
The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, and hematology. Additional information concerning programmatic areas at NIDDK is available at www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx and applicants are strongly encouraged to discuss research priorities with the Scientific Contact.
This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data.
Risky alcohol use can result in a wide range of negative health and social consequences and over time, can result in serious medical conditions, such as hypertension, liver disease, and various types of cancer. Prenatal alcohol exposure can result in fetal alcohol spectrum disorders in the developing baby and is associated with other poor birth outcomes, such as miscarriage, stillbirth, preterm birth, and sudden infant death syndrome.
Group items tagged 
